PMID- 35779938 OWN - NLM STAT- MEDLINE DCOM- 20220707 LR - 20230703 IS - 1524-4733 (Electronic) IS - 1098-3015 (Print) IS - 1098-3015 (Linking) VI - 25 IP - 7 DP - 2022 Jul TI - An Exploratory Analysis of the "Was It Worth It?" Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment. PG - 1081-1086 LID - S1098-3015(21)03223-X [pii] LID - 10.1016/j.jval.2021.11.1368 [doi] AB - OBJECTIVES: Asking "Was it worth it?" (WIWI) potentially captures the patient perception of a treatment's benefit weighed against its harms. This exploratory analysis evaluates the WIWI questionnaire as a metric of patients' perspectives on the worthwhileness of cancer treatment. METHODS: A 3-item WIWI questionnaire was assessed at end of treatment in patients with cancer on the COMET-2 trial (NCT01522443). WIWI items were evaluated to determine their association with quality of life (QOL), treatment duration, end-of-treatment reason, patient-reported adverse events (AEs), and disease response. RESULTS: A total of 65 patients completed the questionnaire; 40 (62%), 16 (25%), and 9 (14%) patients replied yes, uncertain, and no to "Was it worthwhile for you to receive the cancer treatment given in this study?" (item 1), respectively; 39 (60%), 12 (18%), and 14 (22%) to "If you had to do it over again, would you choose to have this cancer treatment?"; and 40 (62%), 14 (22%), and 11 (17%) to "Would you recommend this cancer treatment to others?" Patients responding yes to item 1 remained on treatment longer than those responding uncertain or no (mean 23.0 vs 11.3 weeks, P<.001). Patients responding uncertain/no to item 1 discontinued treatment because of AEs more frequently than those responding yes (36% vs 7.5%, P=.004) and demonstrated meaningful decline in QOL from baseline (-2.5 vs -0.2 mean change, P<.001). Associations between WIWI responses and most patient-reported AEs or treatment efficacy did not reach statistical significance. CONCLUSIONS: Patients who responded affirmatively on WIWI items remained on therapy longer, were less likely to stop treatment because of AEs, and demonstrated superior QOL. The WIWI may inform clinical practice, oncology research, and value frameworks. CI - Copyright (c) 2021 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc. All rights reserved. FAU - Thanarajasingam, Gita AU - Thanarajasingam G AD - Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: thanarajasingam.gita@mayo.edu. FAU - Basch, Ethan AU - Basch E AD - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. FAU - Mead-Harvey, Carolyn AU - Mead-Harvey C AD - Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA. FAU - Bennett, Antonia V AU - Bennett AV AD - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. FAU - Mazza, Gina L AU - Mazza GL AD - Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA. FAU - Schwab, Gisela AU - Schwab G AD - Exelixis Inc, South San Francisco, CA, USA. FAU - Roydhouse, Jessica AU - Roydhouse J AD - Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia and Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, USA. FAU - Rogak, Lauren J AU - Rogak LJ AD - Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA. FAU - Dueck, Amylou C AU - Dueck AC AD - Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA. LA - eng SI - ClinicalTrials.gov/NCT01522443 GR - KL2 TR002379/TR/NCATS NIH HHS/United States GR - P30 CA008748/CA/NCI NIH HHS/United States GR - U01 CA233046/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220103 PL - United States TA - Value Health JT - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research JID - 100883818 SB - IM MH - Humans MH - Medical Oncology MH - *Neoplasms/therapy MH - *Quality of Life MH - Reproducibility of Results MH - Surveys and Questionnaires PMC - PMC9250647 MID - NIHMS1768582 OTO - NOTNLM OT - adverse events OT - patient perspective OT - patient-reported outcomes OT - tolerability OT - toxicity OT - value COIS- Conflict of Interest Disclosures: Dr Bennett reported receiving personal fees from Exelixis Inc during the conduct of this study. Dr Dueck reported receiving grants from the National Cancer Institute during the conduct of the study. Dr Basch reported receiving personal fees from AstraZeneca, Carevive Systems, Navigating Cancer, and Sivan Healthcare outside the submitted work. Dr Roydhouse reported receiving personal fees from Amgen outside the submitted work. Dr Schwab is employed by, and reported stock ownership in Exelixis Inc. No other disclosures were reported. EDAT- 2022/07/03 06:00 MHDA- 2022/07/08 06:00 PMCR- 2023/07/01 CRDT- 2022/07/02 21:05 PHST- 2021/07/20 00:00 [received] PHST- 2021/09/24 00:00 [revised] PHST- 2021/11/16 00:00 [accepted] PHST- 2022/07/02 21:05 [entrez] PHST- 2022/07/03 06:00 [pubmed] PHST- 2022/07/08 06:00 [medline] PHST- 2023/07/01 00:00 [pmc-release] AID - S1098-3015(21)03223-X [pii] AID - 10.1016/j.jval.2021.11.1368 [doi] PST - ppublish SO - Value Health. 2022 Jul;25(7):1081-1086. doi: 10.1016/j.jval.2021.11.1368. Epub 2022 Jan 3.